Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00063089
Other study ID # Nabi-1407
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received June 19, 2003
Last updated May 10, 2012
Start date September 2002
Est. completion date September 2004

Study information

Verified date May 2012
Source Nabi Biopharmaceuticals
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Altastaph has been developed to help the removal of S. aureus from the bloodstream. The main objective of this study will be to test the safety and behavior of Altastaph in patients with S.aureus bacteremia and continuing fever


Description:

Staphylococcus aureus has been recognized as an important community - acquired and nosocomial pathogen. Because it is a common cause of osteomyelitis, endocarditis, and meningitis, S. aureus infections lead to considerable morbidity and mortality. The main objective of this study will be to test the safety and pharmacokinetics of Altastaph in patients with S. aureus bacteremia and persistent fever. This study will also assess the efficacy of Altastaph versus control.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date September 2004
Est. primary completion date September 2004
Accepts healthy volunteers No
Gender Both
Age group 7 Years and older
Eligibility Inclusion Criteria:

- Male or female greater than or equal to 7 years of age

- Weight less then or equal to 150 kilograms

- Subjects willing to complete the full duration of the study, including the follow up visit to day 42

- Life expectancy will enable the subject to complete the duration of the study

- Female subjects of child-bearing potential, negative serum pregnancy test prior to the first infusion of study material. Female subjects of child-bearing potential must agree to use an effective method of birth control throughout the study. Abstinence is not considered an adequate birth control measure. Female subjects of non-child-bearing potential must have history of hysterectomy, bilateral surgical or radiation-induced oophorectomy, tubal ligation or evidence of post menopausal status

- Subject, legal guardian(s) or medical power of attorney must have given written informed consent/ assent

- S. aureus bacteremia and persistent fever. S. aureus bacteremia is defined as the first blood culture positive for S. aureus (index blood culture). Persistent fever (qualifying fever) is defined as a temperature (greater then or equal to 100.4F or greater then or equal to 38C) occuring at least 24 hours after the index temperature was recorded and after the index blood culture was drawn

- Absolute Neutrophil Count (ANC) greater then or equal to 500 x 10^9 cells/L

- Subjects with malignancies may participate if:(1) The malignancy is a solid tumor (i.e. not lymphoma, leukemia, etc.)(2) The tumor has not metastasized to the bone marrow

Exclusion Criteria:

- Known hypersensitivity or previous anaphylaxis to polysaccharide or polysaccharide-conjugate vaccines or to any component of Altastaph

- Profound disability, assessed by the investigator, which would prevent participation in the study

- Known IgA deficiency

- Known HIV infection with CD4 count < 200 cells/L

- Presence of any conditions which, in the opinion of the investigator, places the subject at undo risk or potentially jeopardizes the quality of the data to be generated

- Pregnancy or breast feeding

- Use of investigational drug or biologic in the four weeks prior to screening and during the study. The only exception is use of investigational antineoplastic product if, and only if: (1) The product is not expected to result in sever and prolonged immunosuppression (2) The product is, itself, not immunologically-based (e.g. anti-tumor/ monoclonal antibodies, cancer vaccines or interleukins

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
S. aureus Immune Globulin Intravenous (Human) 5%


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Nabi Biopharmaceuticals

Outcome

Type Measure Description Time frame Safety issue
Primary Safety 6 weeks Yes
Secondary pharmacokinetics 6 weeks No
Secondary Efficacy 6 Weeks No
See also
  Status Clinical Trial Phase
Completed NCT01447407 - Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine Phase 1
Recruiting NCT00518076 - Staphylococcus Aureus Carriers Students Nursing Oxacillin Resistant N/A
Completed NCT01324440 - Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002) Phase 1
Completed NCT00501150 - Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections N/A
Completed NCT00071214 - Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis Phase 3
Completed NCT00175370 - Vancomycin Study: Treatment of Catheter Related Bloodstream Infection Caused by Coagulase Negative Staphylococcus N/A
Recruiting NCT03456544 - Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China
Completed NCT02557568 - Evaluation of an Algorithm for Identifying Persistent Nasal Staphylococcus Aureus Carriage in a Cohort of Healthy Volunteers and Patients Regularly Monitored at the CHU of Saint-Etienne N/A
Terminated NCT01196169 - Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty Phase 4
Completed NCT02640937 - Biofilm Formation in Staphylococcus Epidermidis Associated Implant Infections N/A
Completed NCT02971657 - Bacterial Phenotype of Staphylococcus Aureus Has no Effect on Patients` Clinical Outcome in Orthopedic Device Related Bone Infections N/A
Completed NCT01431326 - Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Completed NCT00303069 - V710 First-In-Man (FIM) Study (V710-001) Phase 1
Completed NCT00156377 - Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections Phase 4
Completed NCT00631566 - Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons N/A
Completed NCT00113191 - Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants N/A
Completed NCT02782078 - Pharmacological Interaction of Rifampicin on Clindamycin in Staphylococcic Osteoarticular Infections N/A
Completed NCT00859677 - Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection
Completed NCT00211900 - Evaluation of Manufacturing Lot of StaphVAX Phase 3
Completed NCT02492958 - SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults Phase 2

External Links